Acute Poisoning with Methadone (Dolphin) (Review)

Most publications report on the use of methadone as a medication, however an increase of the illegal use of methadone has been demonstrated worldwide over the recent years, thus increasing the number of hospitalizations due to acute poisoning with this synthetic opioid. The aim of the present review was to summarize current data on the mechanisms of toxicity, selective toxicity, toxicokinetics and toxicodynamics of methadone (Dolphin). The involvement of CNS, respiratory, cardiovascular and urinary systems in acute poisoning with methadone was dis- cussed. The practice of use of methadone in many countries as a medicine for the replacement therapy for opiate addicts was analyzed. In addition, it was suggested that the results of the use of naloxone antidote therapy in acute opioid poisoning do not always clearly demonstrate its sufficient efficacy. Ways to improve of the intensive therapy of severe acute poisoning by methadone were substantiated; in addition to general critical care methods, treatment with a complex metabolic antihypoxant cytoflavin should be considered. 

1. Luzhnikov E.A., Kostomarova L.G. Acute poisonings. Manual for doctors. Moscow: Meditsina Publishers; 2000: 434. [In Russ.]

2. Loladze A.T., Livanov G.A., Batotsyrenov B.V., Kovalenko A.L., Lodyagin A.N., Glushkov S.I., Baranov D.V., Antonova A.M., Kharitonova T.V. Acute diacetylmorphine (heroin) intoxication (review). Obshchaya Reanimatologiya = General Reanimatology. 2016; 12 (6): 64–81. http://dx.doi.org/10.15360/1813-9779-2016-6-64-81. [In Russ., In Engl.]

3. Batotsyrenov B.V., Livanov G.A., Andrianov A.Y., Vasilyev S.A., Kuznetsov O.A. The clinical course and correction of metabolic distur- bances in patients with severe methadone poisoning. Obshchaya Reanimatologiya = General Reanimatology. 2013; 9 (2): 18–22. http://dx.doi.org/10.15360/1813-9779-2013-2-18. [In Russ., In Engl.]

4. Methadone diversion, abuse, and misuse: deaths increasing at alarming rate. National Drug Intelligence Center, U.S. Department of Justice. Washington, DC, USA, 2007. https://www.justice.gov/archive/ndic/ pubs25/25930/index.htm

5. Marcus S.M. Accidental death from take home methadone maintenance doses: a report of a case and suggestions for prevention. Child Abuse Negl. 2011; 35 (1): 1–2. http://dx.doi.org/10.1016/j.chi- abu.2010.08.003. PMID: 21316105

6. Buster M.C., van Brussel G.H., van den Brink W. An increase in overdose mortality during the first 2 weeks after entering or re-entering methadone treatment in Amsterdam. Addiction. 2002: 97 (8): 993–1001. https://doi.org/10.1046/j.1360-0443.2002.00179.x. PMID: 12144602

7. Elzey M.J., Barden S.M., Edwards E.S. Patient characteristics and out- comes in unintentional, non-fatal prescription opioid overdoses: a sys- tematic review. Pain Physician. 2016; 19 (4): 215–228. PMID: 27228510

8. Ellenhorn M.J., Barceloux D.G. Medical toxicology: diagnosis and treat- ment of human poisoning. New York, NY: Elsevier Scientific Publ. Co.; 1988: 1512.

9. Hoffman R., Howland M.A., Lewin N., Nelson L., Goldfrank L. Goldfrank’s Toxicologic Emergencies, 10th ed. New York, NY: McGraw-Hill; 2015: 1904.

10. Bockmühl M., Ehrhart G. Über eine neue Klasse von spasmolytisch und analgetisch wirkenden Verbindungen, I. Justus Liebigs Annalen der Chemie. 1949; 561 (1): 52–85.

11. Preston A., O’Connor S. The Methadone Handbook. 3id ed. UK: Island Press; 1996: 36.

12. The list of narcotic drugs and psychotropic substances, the turnover of which in the Russian Federation is prohibited in accordance with the laws of the Russian Federation and international treaties of the Russian Federation (list I). http://www.yourist-ufa.ru/criminal-law- news/577-228-2281-229-2291.html. [In Russ.]

13. Gourlay D.L., Heit H.A., Almahrezi A. Universal precautions in pain medicine: a rational approach to the treatment of chronic pain. Pain Med. 2005; 6 (2): 107–112. http://dx.doi.org/10.1111/j.1526- 4637.2005.05031.x. PMID: 15773874

14. Vergeichik T.Kh. Toxicological chemistry. Moscow: MEDpress-inform; 2009: 200.

15. Reisine T., Pasternak G. Opioid analgesics and antagonists. In: Limbird L.E., Hardman J.G. (eds.). Goodman and Gilman’s The Pharmacologic Basis of Therapeutics. 9th ed. NewYork: McGraw-Hill; 1996: 521–555.

16. Eap C.B., Buclin T., Baumann P. Interindividual variability of the clin- ical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin. Pharmacokinet. 2002; 41 (14): 1153–1193. http://dx.doi.org/ 10.2165/00003088-200241140-00003. PMID: 12405865

17. de Castro J., Aguirre C., Rodríguez Sasiaín J.M., Gómez E., Garrido M.J., Calvo R. The effect of changes in gastric pH induced by omeprazole on the absorption and respiratory depression of methadone. Biopharm. Drug Dispos. 1996; 17 (7): 551–563. http://dx.doi.org/10.1002/ (SICI)1099-081X(199610)17:7<551::AID-BDD967>3.0.CO;2-1. PMID: 8894114

18. Ferrari A., Coccia C.P., Bertolini A., Sternieri E. Methadone–metabolism, pharmacokinetics and interactions. Pharmacol. Res. 2004; 50 (6): 551–559. http://dx.doi.org/10.1016/j.phrs.2004.05.002. PMID: 15501692

19. Dale O., Sheffels P., Kharasch E.D. Bioavailabilities of rectal and oral methadone in healthy subjects. Br. J. Clin. Pharmacol. 2004; 58 (2): 156–162. http://dx.doi.org/10.1111/j.1365-2125.2004.02116.x. PMID: 15255797

20. Grabinski P.Y., Kaiko R.F., Rogers A.G., Houde R.W. Plasma levels and analgesia following deltoid and gluteal injections of methadone and morphine. J. Clin. Pharmacol. 1983; 23 (1): 48–55. https://doi.org/ 10.1002/j.1552-4604.1983.tb02704.x. PMID: 6841658

21. de Vos J.W., Geerlings P.J., van den Brink W., Ufkes J.G., van Wilgenburg H. Pharmacokinetics of methadone and its primary metabolite in 20 opiate addicts. Eur. J. Clin. Pharmacol. 1995; 48 (5): 361–366. https://doi.org/10.1007/BF00194951. PMID: 8641323

22. Blinick G., Inturrisi C.E., Jerez E., Wallach R.C. Amniotic fluid methadone in women maintained on methadone. Mt. Sinai J. Med. 1974; 41 (2): 254–259. PMID: 4544621

23. Blinick G., Inturrisi C.E., Jerez E., Wallach R.C. Methadone assays in preg- nant women and progeny. Am. J. Obstet. Gynecol. 1975; 121 (5): 617–621. https://doi.org/10.1016/0002-9378(75)90461-5. PMID: 1115163

24. Eap C.B., Cuendet C., Baumann P. Binding of d-methadone, l- methadone, and dl-methadone to proteins in plasma of healthy volun- teers: role of the variants of alpha 1-acid glycoprotein. Clin. Pharmacol. Ther. 1990; 47 (3): 338–346. https://doi.org/10.1038/clpt.1990.37. PMID: 2311335

25. Wilkins J.N., Ashofteh A., Setoda D., Wheatley W.S., Huigen H., Ling W. Ultrafiltration using the AmiconMPS-1 for assessing methadone plasma protein binding. Ther. Drug Monit. 1997; 19 (1): 83–87. https://doi.org/ 10.1097/00007691-199702000-00015. PMID: 9029753

26. Abramson F.P. Methadone plasma protein binding: alterations in cancer and displacement from alpha 1-acid glycoprotein. Clin. Pharmacol. Ther. 1982; 32 (5): 652–658. https://doi.org/10.1038/clpt.1982.217. PMID: 7128006

27. Romach M.K., Piafsky K.M., Abel J.G., KhouwV., Sellers E.M. Methadone binding to orosomucoid (alpha 1-acid glycoprotein): determinant of free fraction in plasma. Clin. Pharmacol. Ther. 1981; 29 (2): 211–217. https://doi.org/10.1038/clpt.1981.34. PMID: 7193106

28. Malpas T.J., Darlow B.A., Lennox R., Horwood L.J. Maternal methadone dosage and neonatal withdrawal. Aust. N Z J. Obstet. Gynaecol. 1995; 35 (2): 175–177. http://dx.doi.org/10.1111/j.1479-828X.1995.tb01863.x. PMID: 7677682

29. Neonatal drug withdrawal. Pediatrics. 1983; 72 (6): 895–902. PMID: 6139783

30. Wojnar-Horton R.E., Kristensen J.H., Yapp P., Ilett K.F., Dusci L.J., Hackett L.P. Methadone distribution and excretion into breast milk of clients in a methadone maintenance programme. Br. J. Clin. Pharmacol. 1997; 44 (6): 543–547. https://doi.org/10.1046/j.1365-2125.1997. t01-1-00624.x. PMID: 9431829

31. McCarthy J.J., Posey B.L. Methadone levels in human milk. J. Hum. Lact. 2000; 16 (2): 115–120. https://doi.org/10.1177/089033440001600206. PMID: 11153342

32. Begg E.J., Malpas T.J., Hackett L.P., Ilett K.F. Distribution of R- and S- methadone into human milk during multiple, medium to high oral dos- ing. Br. J. Clin. Pharmacol. 2001; 52 (6): 681–685. https://doi.org/ 10.1046/j.0306-5251.2001.01506.x. PMID: 11736879

33. Beckett A.H., Taylor J.F., Casy A.F., Hassan M.M. The biotransformation of methadone in man: synthesis and identification of a major metabo- lite. J. Pharm. Pharmacol. 1968; 20 (10): 754–762.https://doi.org/ 10.1111/j.2042-7158.1968.tb09634.x. PMID: 4386743

34. Verebely K., Volavka J., Mulé S., Resnick R. Methadone in man: pharmacokinetic and excretion studiesin acute and chronic treatment. Clin. Pharmacol. Ther. 1975; 18 (2): 180–190. https://doi.org/10.1002/ cpt1975182180. PMID: 1149368

35. Anggård E., Gunne L.M., Homstrand J., McMahon R.E., Sandberg C.G., Sullivan H.R. Disposition of methadone in methadone maintenance. Clin. Pharmacol. Ther. 1975; 17 (3): 258–266. https://doi.org/ 10.1002/cpt1975173258. PPMID: 1120392

36. Iribarne C., Berthou F., Baird S., Dréano Y., Picart D., Bail J.P., Beaune P., Ménez J.F. Involvement of cytochrome P450 3A4 enzyme in the N- demethylation of methadone in human liver microsomes. Chem. Res. Toxicol. 1996; 9 (2): 365–373. http://dx.doi.org/10.1021/tx950116m. PMID: 8839037

37. Moody D.E., Alburges M.E., Parker R.J., Collins J.M., Strong J.M. The involvement of cytochrome P4503A4 in the N-demethylation of L- alpha-acetylmethadol (LAAM), norLAAM, and methadone. Drug Metab. Dispos. 1997; 25 (12): 1347–1353. PMID: 9394023

38. Peng P.W., Tumber P.S., Gourlay D. Review article: perioperative pain management of patients on methadone therapy. Can. J Anaesth. 2005; 52 (5): 513–523. http://dx.doi.org/10.1007/BF03016532. PMID: 15872131

39. Kharasch E.D., Hoffer C., Whittington D., Sheffels P. Role of hepatic and intestinal cytochrome P450 3Aand 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin. Pharmacol. Ther. 2004; 76 (3): 250–269. http://dx.doi.org/10.1016/j.clpt.2004.05.003. PMID: 15371986

40. Foster D.J., Somogyi A.A., Bochner F. Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4. Br. J. Clin. Pharmacol. 1999; 47 (4): 403–412. https://doi.org/10.1046/j.1365-2125.1999.00921.x. PMID: 10233205

41. Bertschy G., Eap C.B., Powell K., Baumann P. Fluoxetine addition to methadone in addicts: pharmacokinetic aspects. Ther. Drug Monit. 1996; 18 (5): 570–572. https://doi.org/10.1097/00007691- 199610000-00008. PMID: 8885121

42. Eap C.B., Bertschy G., Powell K., Baumann P. Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of methadone. J. Clin. Psychopharmacol. 1997; 17 (2): 113–117. https://doi.org/10.1097/00004714-199704000-00010. PMID: 10950475

43. Gerber J.G., Rhodes R.J., Gal J. Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality. 2004; 16 (1): 36–44. http://dx.doi.org/10.1002/chir.10303. PMID: 14628297

44. Wang J.S., DeVane C.L. Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro. Drug Metab. Dispos. 2003; 31 (6): 742–747. https://doi.org/10.1124/ dmd.31.6.742. PMID: 12756206

45. Mégarbane B., Declèves X., Bloch V., Bardin C., Chast F., Baud F.J. Case report: quantification of methadone-induced respiratory depression using toxicokinetic/toxicodynamic relationships. Crit. Care. 2007; 11 (1): R5. http://dx.doi.org/10.1186/cc5150. PMID: 17224045

46. Ebert B., Thorkildsen C., Andersen S., Christrup L.L., Hjeds H. Opioid analgesics as noncompetitive N-methyl-D-aspartate (NMDA) antago- nists. Biochem. Pharmacol. 1998; 56 (5): 553–559. https://doi.org/ 10.1016/S0006-2952(98)00088-4. PMID: 9783723

47. Liu J.G., Anand K.J. Protein kinases modulate the cellular adaptations associated with opioid tolerance and dependence. Brain Res. Brain Res. Rev. 2001; 38 (1–2): 1–19. https://doi.org/10.1016/S0165- 0173(01)00057-1. PMID: 11750924

48. Mao J. NMDA and opioid receptors: their interactions in antinociception, tolerance and neuroplasticity. Brain Res. Brain Res. Rev. 1999; 30 (3): 289–304. https://doi.org/10.1016/S0165-0173(99)00020-X. PMID: 10567729

49. Lugo R.A., Satterfield K.L., Kern S.E. Pharmacokinetics of methadone. J. Pain Palliat. Care Pharmacother. 2005; 19 (4): 13–24. https://doi.org/ 10.1080/J354v19n04_05. PMID: 16431829

50. Rando J., Szari S., Kumar G., Lingadevaru H. Methadone overdose causing acute cerebellitis and multi-organ damage. Am. J. Emerg. Med. 2016; 34 (2): 343.e1-3. http://dx.doi.org/10.1016/j.ajem.2015.06.032. PMID: 26164407

51. Isaacson J.E., Vora N.M. Differential diagnosis and treatment of hearing loss. Am. Fam. Physician. 2003; 68 (6): 1125–1132. PMID: 14524400

52. Oh A.K., Ishiyama A., Baloh R.W. Deafness associated with abuse of hydrocodone/acetaminophen. Neurology. 2000; 54 (12): 2345. https://doi.org/10.1212/WNL.54.12.2345. PMID: 10881270

53. Ishiyama A., Ishiyama G., Baloh R.W., Evans C.J. Heroin-induced reversible profound deafness and vestibular dysfunction. Addiction. 2001; 96 (9): 1363–1364. PMID: 11683145

54. Shaw K.A., Babu K.M., Hack J.B. Methadone, another cause of opioid-associated hearing loss: a case report. J. Emerg. Med. 2011; 41 (6): 635–639. http://dx.doi.org/10.1016/j.jemermed.2010.11.014. PMID: 21145191

55. Chevillard L., Mégarbane B., Baud F.J., Risède P., Declèves X., Mager D., Milan N., Ricordel I. Mechanisms of respiratory insufficiency induced by methadone overdose in rats. Addict. Biol. 2010; 15 (1): 62–80. http://dx.doi.org/10.1111/j.1369-1600.2009.00184.x. PMID: 20002023

56. Swegle J.M., Wensel D.D. The safety of methadone hydrochloride. Expert Opin. Drug Saf. 2008; 7 (1): 5–8. http://dx.doi.org/10.1517/ 14740338.7.1.5. PMID: 18171310

57. Fone K.C., Wilson H. The effects of alfentanil and selected narcotic analgesics on the rate of action potential discharge of medullary respiratory neurones in anaesthetized rats. Br. J. Pharmacol. 1986; 89 (1): 67–76. https://doi.org/10.1111/j.1476-5381.1986.tb11121.x. PMID: 2879593

58. van den Hoogen R.H., Colpaert F.C. Respiratory effects of morphine in awake unrestrained rats. J. Pharmacol. Exp. Ther. 1986; 237 (1): 252–259. PMID: 3083095

59. Shook J.E., Watkins W.D., Camporesi E.M. Differential roles of opioid receptors in respiration, respiratory disease, and opiate-induced respi- ratory depression. Am. Rev. Respir. Dis. 1990; 142 (4): 895–909. http://dx.doi.org/10.1164/ajrccm/142.4.895. PMID: 2171388

60. Bailey P.L., Lu J.K., Pace N.L., Orr J.A., White J.L., Hamber E.A., Slawson M.H., Crouch D.J., Rollins D.E. Effects of intrathecal morphine on the ventilatory response to hypoxia. N. Engl. J. Med. 2000 26; 343 (17): 1228–1234. http://dx.doi.org/10.1056/NEJM200010263431705. PMID: 11071674

61. Pfeiffer A., Feuerstein G., Kopin I.J., Faden A.I. Cardiovascular and respiratory effects of mu-, delta- and kappa-opiate agonists microinjected into the anterior hypothalamic brain area of awake rats. J. Pharmacol. Exp. Ther. 1983; 225 (3): 735–741. PMID: 6306217

62. Zyroff J., Slovis T.L., Nagler J. Pulmonary edema induced by oral methadone. Radiology. 1974; 112 (3): 567–568. http://dx.doi.org/ 10.1148/112.3.567. PMID: 4843287

63. Wilson K.C., Saukkonen J.J. Acute respiratory failure from abused sub- stances. J. Intensive Care Med. 2004; 19: 183–193. http://dx.doi.org/ 10.1177/0885066604263918. PMID: 15296619

64. Milroy C.M., Forrest A.R.W. Methadone deaths: a toxicological analysis. J. Clin. Pathol. 2000; 53 (4): 277–281. http://dx.doi.org/10.1136/ jcp.53.4.277. PMID: 10823123

65. Sánchez Hernández A.M., Atienza Fernández F., Arenal Maíz A., González Torrecilla E., Puchol Calderón A., Almendral Garrote J. Torsades de pointes during methadone treatment. Rev. Esp. Cardiol. 2005; 58 (10): 1230–1232. https://doi.org/10.1157/13079918. PMID: 16238992

66. Chugh S.S., Socoteanu C., Reinier K., Waltz J., Jui J., Gunson K. A community-based evaluation of sudden death associated with therapeutic levels of methadone. Am. J. Med. 2008; 121 (1): 66–71. http://dx. doi.org/10.1016/j.amjmed.2007.10.009. PMID: 18187075

67. Cruciani R.A. Methadone: to ECG or not to ECG...That is still the question. J. Pain Symptom. Manage. 2008; 36 (5): 545–552. http://dx.doi.org/10.1016/j.jpainsymman.2007.11.003. PMID: 18440771

68. Wedam E.F., Bigelow G.E., Johnson R.E., Nuzzo P.A., Haigney M.C. QT- interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch. Intern. Med. 2007; 167 (22): 2469–2475. http://dx.doi.org/10.1001/archinte.167.22.2469. PMID: 18071169

69. Walley A.Y., Doe Simkins M., Quinn E., Pierce C., Xuan Z., Ozonoff A. Opioid overdose prevention with intranasal naloxone among people who take methadone. J. Subst. Abuse Treat. 2013; 44 (2): 241–247. http://dx.doi.org/10.1016/j.jsat.2012.07.004. PMID: 22980450

70. Kuznetsov O.A., Batotsyrenov B.V., Lodyagin A.N., Fedorov A.V., Loladze A.T. [Acute kidney injury in cases of poisoning with methadone: caus- es, pathogenesis, therapy]. Narkologiya. 2016; 15 (8): 62–67. [In Russ.]

71. Polettini A., Groppi A., Vignali C., Montagna M. Fully-automated systematic toxicological analysis of drugs, poisons, and metabolites in whole blood, urine, and plasma by gas chromatography-full scan mass spec- trometry. J. Chromatogr. B Biomed. Sci. Appl. 1998; 713 (1): 265–279. http://doi.org/10.1016/S0378-4347(98)00062-0. PMID: 9700563

72. Mendelevich V.D. Methadone dependence and methadone mainte- nance therapy program. Narkologiya. 2007; 6 (9): 67–72. [In Russ.]

73. Nielsen S., Larance B., Degenhardt L., Gowing L., Kehler C., Lintzeris N. Opioid agonist treatment for pharmaceutical opioid dependent people. Cochrane Database Syst. Rev. 2016; 9 (5): CD011117. http://dx.doi.org/10.1002/14651858.CD011117.pub2. PMID: 27157143

74. Mattick R.P., Kimber J., Breen C., Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst. Rev. 2008; 16; (2): CD002207. http://dx.doi.org/10.1002/14651858.CD002207.pub2. PMID: 15266465

75. Vignali C., Stramesi C., Morini L., Pozzi F., Groppi A. Methadone-relat- ed deaths. A ten year overview. Forensic. Sci. Int. 2015; 257: 172–176. http://dx.doi.org/10.1016/j.forsciint.2015.08.017. PMID: 26360592

76. Nadezhdin A.V. Prospects for the introduction of «substitution thera- py» in patients with opioid addiction in Russia. Narkologiya. 2002; 1 (2): 42–44. [In Russ.]

77. Ivanets N.N., Altshuler V.B. «Substitution therapy» of drug addiction with methadone and other opioid drugs: the origin, essence and trends. Voprosy Narkologii. 2004; 2: 3–7. [In Russ.]

78. Coffin P.O., Sullivan S.D. Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal. Ann. Intern. Med. 2013; 158 (1): 1–9. http://dx.doi.org/10.7326/0003-4819-158-1-201301010- 00003. PMID: 23277895

79. Coffin P.O., Sullivan S.D. Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal in Russian cities. J. Med. Econ. 2013; 16 (8): 1051–1060. http://dx.doi.org/10.3111/13696998.2013. 811080. PMID: 23730942

80. Kerr D., Kelly A.M., Dietze P., Jolley D., Barger B. Randomized controlled trial comparing the effectiveness and safety of intranasal and intramus- cular naloxone for the treatment of suspected heroin overdose. Addiction. 2009; 104 (12): 2067–2074. http://dx.doi.org/10.1111/ j.1360-0443.2009.02724.x. PMID: 19922572

81. Sporer K.A., Firestone J., Isaacs S.M. Out-of-hospital treatment of opioid overdoses in an urban setting. Acad. Emerg. Med. 1996; 3 (7): 660–667. https://doi.org/10.1111/j.1553-2712.1996.tb03487.x. PMID: 8816181

82. Centers for Disease Control and Prevention (CDC). Community-based opioid overdose prevention programmes providing naloxone — United States, 2010. MMWR Morb. Mortal. Wkly. Rep. 2012; 61 (6): 101–105. PMID: 22337174

83. Burris S., Norland J., Edlin B.R. Legal aspects of providing naloxone to heroin users in the United States. Int. J. Drug Policy. 2001; 12 (3): 237–248.

84. Just B., Delva E., Camus Y., Lienhart A. Oxygen uptake during recovery following naloxone. Relatoinship with intraoperative heat loss. Anestheziology. 1992; 76 (1): 60–64. https://doi.org/10.1097/ 00000542-199201000-00009. PMID: 1729937

85. Kim H.K., Nelson L.S. Effectiveness of low dose naloxone to reverse res- piratory depression in opioid intoxication. Clin. Toxicol. 2012; 50 (7): 577–578.

86. Luzhnikov E.A., Sukhodolova G.N. Clinical toxicology. Moscow: Meditsinskoe Informatsionnoe Agentstvo; 2008: 576.

87. Luzhnikov E.A., Ilyashenko K.K., Yastrebova E.V., Kalyanova N.A., Epifanova N.M., Goldfarb Yu.S., Petrov S.I., Badalyan A.V., Melkonyan Sh.L., Matkevich V.A., Sukhodolova G.N., Livanov A.S., Elkov A.N., Marchenkova L.V. Clinical presentation, diagnosis and treatment of acute drug poisoning. Guidelines. Moscow: NII SP Imeni N.V. Sklifosovskogo; 2000: 12. [In Russ.]

88. Shilov V.V., Batotsyrenov B.V., Vasilyev S.A., Shikalova I.A., Loladze A.T. Correction of nonspecific damages in acute poisoning of substance from the group of opiate drug in patients in critical condition. Voenno Meditsinsky Zhurnal. 2011; 332 (11): 36–39. PMID: 22329170. [In Russ.]

89. Alekhnovich A.V., Ilyashenko K.K., Yelkov A.N., Lezhenina N.F., Livanov A.S. Comparative assessment of the clinical efficacy of antihypoxants in patients with acute poisoning by psychotropic agents. Obshchaya Reanimatologiya = General Reanimatology. 2009; 5 (1): 58–60. http://dx.doi.org/10.15360/1813-9779-2009-1-58. [In Russ., In Engl.]

90. Livanov G.A., Lodyagin A.N., Batotsyrenov B.V., Loladze A.T., Glushkov S.I., Kovalenko A.L. The use of reamberin in combined intensive care of acute poisoning. Klinicheskaya Meditsina. 2016; 94 (5): 339–346. http://dx.doi.org/10.18821/0023-2149-2016-94-5-340-347. [In Russ.]

91. Aleksandrovich Yu.S, Pshenisnov K.V. Infusion antihypoxants in chil- dren with critical conditions. Obshchaya Reanimatologiya = General Reanimatology. 2014; 10 (3): 59–74. http://dx.doi.org/10.15360/ 1813-9779-2014-3-59-74. [In Russ., In Engl.]

92. Orlov Y.P., Govorova N.V. Role of succinates in critical conditions. Obshchaya Reanimatologiya = General Reanimatology. 2014; 10 (6): 65–82. http://dx.doi.org/10.15360/1813-9779-2014-6-65-82. [In Russ., In Engl.]

93. Ivnitsky Yu.Yu. Succinic acid in the system of metabolic correction of the functional state and resistance of the organism. Sankt Peterburg: 1998; 82. [In Russ.]

94. Aleksandrov M.V., Vasilyev S.A., Kuznetsov O.A., Andrianov A.Yu., Shikalova I.A., Loladze A.T., Batotsyrenov B.V. The use of cytoflavin in combined neurometabolic therapy of acute cerebral insufficiency associated with acute poisoning with neurotropic poisons. Klinicheskaya Meditsina. 2010; 88 (2): 58–61. PMID: 21105475. [In Russ.]

95. Kwong L.K., Sohal R.S. Substrate and site specificity of hydrogen peroxide generation in mouse mitochondria. Arch. Biochem. Biophys. 1998; 350 (1): 118–126. http://dx.doi.org/10.1006/abbi.1997.0489. PMID: 9466828

96. Suzuki M., Muraoka H., Kurata M., Agar N.S. Glutathione reductase activity and flavin concentration in guinea-pig tissues. Exp. Anim. 1999; 48 (3): 199–202. https://doi.org/10.1538/expanim.48.199. PMID: 10480025

97. Thiemermann C., Bowes J., Myint F.P., Vane J.R. Inhibition of the activity of poly (ADP ribose) synthetase reduces ischemia-reperfusion injury in the heart and skeletal muscle. Proc. Natl. Acad. Sci. USA. 1997; 94 (2): 679–683. https://doi.org/10.1073/pnas.94.2.679. PMID: 9012844

98. Dunaev V.V., Tishkin V.S., Evdokimov E.I., Belai I.M. The mechanism of action of riboxin. Farmakologiya i Toksikologiya. 1989; 52 (6): 56–58. PMID: 2483141. [In Russ.]